IL145907A0 - Use of glucosylceramide synthesis inhibitors in therapy - Google Patents
Use of glucosylceramide synthesis inhibitors in therapyInfo
- Publication number
- IL145907A0 IL145907A0 IL14590700A IL14590700A IL145907A0 IL 145907 A0 IL145907 A0 IL 145907A0 IL 14590700 A IL14590700 A IL 14590700A IL 14590700 A IL14590700 A IL 14590700A IL 145907 A0 IL145907 A0 IL 145907A0
- Authority
- IL
- Israel
- Prior art keywords
- therapy
- synthesis inhibitors
- glucosylceramide synthesis
- glucosylceramide
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9909064.9A GB9909064D0 (en) | 1999-04-20 | 1999-04-20 | Therapies |
PCT/GB2000/001563 WO2000062780A1 (en) | 1999-04-20 | 2000-04-20 | Use of glucosylceramide synthesis inhibitors in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145907A0 true IL145907A0 (en) | 2002-07-25 |
Family
ID=10851915
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14590700A IL145907A0 (en) | 1999-04-20 | 2000-04-20 | Use of glucosylceramide synthesis inhibitors in therapy |
IL145907A IL145907A (en) | 1999-04-20 | 2001-10-12 | Use of amino acid suppressor of GLUCOSYLCERAMIDE synthesis in the manufacture of drugs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL145907A IL145907A (en) | 1999-04-20 | 2001-10-12 | Use of amino acid suppressor of GLUCOSYLCERAMIDE synthesis in the manufacture of drugs |
Country Status (12)
Country | Link |
---|---|
US (1) | US6683076B2 (no) |
EP (1) | EP1171129A1 (no) |
JP (1) | JP2002542195A (no) |
AU (1) | AU776947B2 (no) |
BR (1) | BR0009868A (no) |
CA (1) | CA2368814C (no) |
GB (1) | GB9909064D0 (no) |
IL (2) | IL145907A0 (no) |
MX (1) | MXPA01010706A (no) |
NO (1) | NO20015112L (no) |
WO (1) | WO2000062780A1 (no) |
ZA (1) | ZA200108413B (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
GB9909066D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
WO2000066105A2 (en) * | 1999-04-30 | 2000-11-09 | The Trustees Of Boston College | Treatment of epilepsy with imino sugars |
US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US7985760B2 (en) | 2002-07-17 | 2011-07-26 | Actelion Pharmaceuticals Ltd. | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase |
EP1554245B1 (en) | 2002-07-17 | 2012-09-26 | Actelion Pharmaceuticals Ltd. | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
MXPA05002292A (es) * | 2002-08-27 | 2006-05-22 | Nestle Sa | Prevencion de tratamiento de tejido epitelial o perdida de pelo. |
GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
GB0313678D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
US20060025449A1 (en) * | 2004-03-25 | 2006-02-02 | United Therapeutics | Use of N-substituted imino sugars for appetite suppression |
US20090111812A1 (en) * | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
US7884115B2 (en) * | 2004-09-28 | 2011-02-08 | Allergan, Inc. | Methods and compositions for the treatment of pain and other neurological conditions |
GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
WO2008086296A2 (en) * | 2007-01-05 | 2008-07-17 | Mount Sinai School Of Medicine | Acid ceramidase and cell survival |
US20140179925A1 (en) | 2009-09-04 | 2014-06-26 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
US9314466B2 (en) | 2007-03-06 | 2016-04-19 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
US8173683B2 (en) | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
WO2008109287A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
ES2711075T3 (es) * | 2007-03-06 | 2019-04-30 | Allergan Inc | Compuestos para su uso en el tratamiento de trastornos cognitivos |
US20100105687A1 (en) * | 2007-03-06 | 2010-04-29 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
LT2889043T (lt) | 2008-12-16 | 2019-07-10 | Genzyme Corporation | Sintetiniai tarpiniai junginiai oligosacharido-baltymo konjugatų gamybai |
EP3741384A1 (en) | 2011-09-07 | 2020-11-25 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
EP2854910B1 (en) | 2012-06-01 | 2020-04-15 | Icahn School of Medicine at Mount Sinai | Ceramide levels in the treatment and prevention of infections |
PL2968479T3 (pl) | 2013-03-14 | 2019-10-31 | Icahn School Med Mount Sinai | Kompozycje terapeutyczne ceramidazy kwasowej i sposoby ich wytwarzania i stosowania |
WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
JP2023512281A (ja) | 2020-02-03 | 2023-03-24 | ゲイン セラピューティクス エスアー | Mps1を処置するための併用療法 |
IT202000008917A1 (it) | 2020-04-24 | 2021-10-24 | Biovalley Invest Partner S R L | Composizioni antivirali |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798366A (en) * | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
WO1998002161A1 (en) * | 1996-07-15 | 1998-01-22 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
WO1999001555A1 (en) * | 1997-07-03 | 1999-01-14 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Genes for niemann-pick type c disease |
US6610703B1 (en) * | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
AU6050600A (en) * | 1999-07-26 | 2001-02-13 | G.D. Searle & Co. | Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases |
-
1999
- 1999-04-20 GB GBGB9909064.9A patent/GB9909064D0/en not_active Ceased
-
2000
- 2000-04-20 EP EP00920922A patent/EP1171129A1/en not_active Ceased
- 2000-04-20 MX MXPA01010706A patent/MXPA01010706A/es active IP Right Grant
- 2000-04-20 AU AU41333/00A patent/AU776947B2/en not_active Expired
- 2000-04-20 JP JP2000611916A patent/JP2002542195A/ja active Pending
- 2000-04-20 IL IL14590700A patent/IL145907A0/xx unknown
- 2000-04-20 BR BR0009868-0A patent/BR0009868A/pt not_active Application Discontinuation
- 2000-04-20 WO PCT/GB2000/001563 patent/WO2000062780A1/en active Application Filing
- 2000-04-20 CA CA2368814A patent/CA2368814C/en not_active Expired - Lifetime
-
2001
- 2001-10-12 IL IL145907A patent/IL145907A/en not_active IP Right Cessation
- 2001-10-12 ZA ZA200108413A patent/ZA200108413B/xx unknown
- 2001-10-19 US US10/007,306 patent/US6683076B2/en not_active Expired - Lifetime
- 2001-10-19 NO NO20015112A patent/NO20015112L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2000062780A1 (en) | 2000-10-26 |
US6683076B2 (en) | 2004-01-27 |
EP1171129A1 (en) | 2002-01-16 |
ZA200108413B (en) | 2003-03-26 |
BR0009868A (pt) | 2002-01-08 |
NO20015112L (no) | 2001-12-10 |
MXPA01010706A (es) | 2002-08-20 |
CA2368814A1 (en) | 2000-10-26 |
IL145907A (en) | 2011-05-31 |
JP2002542195A (ja) | 2002-12-10 |
NO20015112D0 (no) | 2001-10-19 |
GB9909064D0 (en) | 1999-06-16 |
AU776947B2 (en) | 2004-09-30 |
CA2368814C (en) | 2010-09-07 |
US20020115667A1 (en) | 2002-08-22 |
AU4133300A (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145907A0 (en) | Use of glucosylceramide synthesis inhibitors in therapy | |
EE200100524A (et) | CYP2D6 inhibiitorite kasutamine kombineeritud ravis | |
IL148719A0 (en) | Kinase inhibitors as therapeutic agents | |
IL166780A0 (en) | Use of ikappab-kinase inhibitors in pain therapy | |
HUP0203289A3 (en) | Benzamides and related inhibitors of factor xa | |
HK1040517A1 (en) | Novel aralkyl amines of spirofuropyridines useful in therapy | |
ZA200306488B (en) | Benzamides and related inhibitors of factor Xa. | |
IL145346A (en) | Dimeric compounds and their use as inhibitors of neuraminidase | |
PL352547A1 (en) | Drugs containing inhibitors of human kinase h-sgk | |
EP1227821A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD FOR USE THEREOF | |
GB0013378D0 (en) | Use of therapeutic benzamide derivatives | |
GB0025782D0 (en) | Use of inhibitors | |
GB0004167D0 (en) | 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents | |
GB0003254D0 (en) | Heterocyclic compounds and their therapeutic use | |
PL352200A1 (en) | Inhibitors of viia agent | |
IL130171A0 (en) | Therapeutic use of melatonin | |
IL131047A0 (en) | Use of il-18 inhibitors | |
AU2001240885A1 (en) | Use of glucosylceramide synthesis inhibitors in brain cancer therapy | |
GB9903919D0 (en) | Aminophenols and their therapeutic use | |
GB9906130D0 (en) | Compounds for use in therapy | |
IL147675A0 (en) | Use of il-18 inhibitors | |
GB0017625D0 (en) | Use of compounds in therapy | |
GB0012945D0 (en) | Use of compounds in therapy | |
GB0030058D0 (en) | Use of compounds in therapy | |
GB9905307D0 (en) | Therapy and use of compounds in therapy |